Detection of clinically insignificant prostate cancer by allelic imbalance analysis

通过等位基因不平衡分析检测临床上不显着的前列腺癌

• 批准号: 18590350
• 负责人: TAKAHASHI Hiroyuki
• 金额: $ 2.12万
• 依托单位: Jikei University School of Medicine
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2006
• 资助国家: 日本
• 起止时间: 2006 至 2007
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18590350/
• 关键词: cancer; pathology; cell. tissue; 前立腺癌; 微小癌; ラテント癌; LOH

The criterion tumor volume (TV) for clinically insignificant prostate cancer has been reported, but it differs from study to study : some have reported TV < 200 mm^3 ; others, <500 mm^3. The aim of the present study was to distinguish clinically insignificant cancers from significant ones using molecular biological methods. A total of 184 microscopic cancers (MC) defined as limited within a 3 mm circle and 82 main tumor (MT) nodules were selected. Thirteen microsatellite loci at 6q22, 8p23.2-23, 13q14 and 13q33 were evaluated for loss of heterozygosity (LOH). MT were subgrouped as TV <500 mm^3 or > 500 mm^3 ; TV < 200 mm^3 or > 200 mm^3 ; and TV < 200 mm^3 or 200 mm^3 〓 TV < 500 mm^3 or〓500 mm^3 ; and frequencies of LOH were compared between these three groups. Frequencies of LOH at 6q16-21, 6q22, 8p23.1, 8p23.2, 13q14 were significantly lower in MC (1.0%, 2.7%, 1.9%, 1.1% and 5.4%) than in MT (30.9%, 40.4%, 12%, 8.7% and 20.6%). No significant differences in LOH frequencies were found at any of these TV settings. When insignificant tumor is defined as TV < 200 mm^3 or < 500 mm^3, it should include tumors with malignant potential equivalent to larger tumors. It is suggested that in order to identify insignificant tumor within a strict safety range, TV should be set lower.

临床上无意义的前列腺癌的标准肿瘤体积（TV）已有报道，但不同研究之间存在差异：一些研究报告TV < 200 mm^3 ;另一些研究报告TV <500 mm^3。本研究的目的是使用分子生物学方法区分临床上不重要的癌症和重要的癌症。选择了总共184个限定在3 mm圆内的显微镜下癌症（MC）和82个主要肿瘤（MT）结节。在6 q22、8p23.2-23、13 q14和13 q33共13个微卫星位点进行杂合性丢失（洛）分析。MT分为TV <500 mm^3或> 500 mm^3、TV < 200 mm^3或> 200 mm^3、TV < 200 mm^3或200 mm^3、TV < 500 mm^3或> 500 mm^3三组，比较三组间洛缺失的发生率。6 q16 -21、6 q22、8p23.1、8p23.2、13 q14位点的洛缺失率在MC中分别为1.0%、2.7%、1.9%、1.1%和5.4%，显著低于MT中的30.9%、40.4%、12%、8.7%和20.6%。在这些TV设置中没有发现洛频率的显著差异。当不显著的肿瘤定义为TV < 200 mm^3或< 500 mm^3时，它应包括具有与较大肿瘤相当的恶性潜能的肿瘤。建议在严格的安全范围内，将TV设置得较低，以识别不重要的肿瘤。

项目成果

Prediction of clinically insignificant prostate cancer by detection of allelicimbalance at 6q,8p and 13q

通过检测 6q、8p 和 13q 等位基因不平衡来预测临床上不显着的前列腺癌

• 期刊: Pathol Int (印刷中)
• 作者: Nakano M;Takahashi H;et. al.
• 通讯作者: et. al.

Prediction of clinically insignificant prostate cancer by detection of allelic imbalance at 6q, 8p and 13q

通过检测 6q、8p 和 13q 等位基因不平衡来预测临床上不显着的前列腺癌

• 发表时间: 2008
• 期刊: Pathol Int 58
• 作者: Nakano;M;Takahashi;H;et. al.
• 通讯作者: et. al.

Therapeutic applications of allelic imbalance and immunohistochemistry in prostate cancers

等位基因失衡和免疫组织化学在前列腺癌中的治疗应用

• 发表时间: 2007
• 作者: Nakano M;Takahashi H;et. al.;Takahashi H
• 通讯作者: Takahashi H

Prediction of clinically insignificant prostate cancer by detection of allelic imbalance at 6q,8p and 13q

通过检测 6q、8p 和 13q 等位基因失衡预测临床上不显着的前列腺癌

• 发表时间: 2008
• 期刊: Pathol Int
• 影响因子: 2.2
• 作者: Nakano M;Takahashi H;et. al.
• 通讯作者: et. al.

13q,6q,8p領域LOH解析による前立腺微小癌と主腫瘍の差

13q、6q、8p区域LOH分析前列腺微小癌与主肿瘤的差异

• 发表时间: 2007
• 作者: 中野 雅貴;鷹橋 浩幸;ら
• 通讯作者: ら